^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK1 inhibitor

    Related drugs:
    22h
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial primary completion date
    |
    azacitidine • Ojjaara (momelotinib)
    1d
    A Trial of Baricitinib in Patients With Cardiac Sarcoidosis (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Stanford University | Trial completion date: Apr 2028 --> Dec 2028 | Initiation date: Jul 2025 --> Apr 2026 | Trial primary completion date: Jan 2028 --> Jul 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    1d
    Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Completed --> Active, not recruiting | Trial completion date: Mar 2024 --> Feb 2027 | Trial primary completion date: Mar 2024 --> Feb 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    NCI-2022-02385: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, Jonathan Brammer | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    Jakafi (ruxolitinib)
    1d
    JAKUVEITE: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (clinicaltrials.gov)
    P3, N=33, Not yet recruiting, University Hospital, Rouen | Trial completion date: Aug 2026 --> Aug 2029 | Trial primary completion date: Aug 2023 --> Aug 2029
    Trial completion date • Trial primary completion date
    3d
    An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=59, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • itacitinib (INCB039110) • simmitinib (SYHA1817)
    6d
    STOP-HS LTE: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P3, N=617, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=960 --> 617
    Enrollment closed • Enrollment change
    6d
    UP-FOR-U: Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (clinicaltrials.gov)
    P4, N=200, Not yet recruiting, CARE ARTHRITIS LTD. | Trial completion date: Dec 2026 --> May 2027 | Initiation date: Nov 2025 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    6d
    SELECT AXIS RW: Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan (clinicaltrials.gov)
    P=N/A, N=69, Completed, AbbVie | Recruiting --> Completed | N=100 --> 69
    Trial completion • Enrollment change • Adverse events • Real-world evidence
    6d
    Upadacitinib for the management of refractory hidradenitis suppurativa, psoriasis, and pyoderma gangrenosum. (PubMed, Dermatol Reports)
    When these conditions occur together, management becomes particularly challenging and may require therapeutic strategies targeting broad inflammatory networks. [...].
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    6d
    Obesity- and tumor-derived signals drive cancer-associated state transitions in breast mesenchymal stromal/stem cells reprogrammed by IL1RA or JAK inhibition. (PubMed, Exp Hematol Oncol)
    Mechanistically, IL1 receptor blockade (anakinra) or JAK inhibition (AZD1480) reverses both iCAF and myCAF phenotypes and functionally suppresses stromal-driven epithelial-mesenchymal transition as well as cancer stemness in breast cancer cells. These findings establish a mechanistic link between obese cues, stromal plasticity, and breast cancer progression, and reveal IL1/JAK signaling as a tractable axis to therapeutically reprogram the breast cancer stroma.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • IL1R1 (Interleukin 1 receptor, type I)
    |
    AZD1480 • Kineret (anakinra)
    8d
    UVIPWP: Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis (clinicaltrials.gov)
    P=N/A, N=70, Completed, Peking University First Hospital
    New trial
    |
    IL17A (Interleukin 17A)